Literature DB >> 25992276

Impact of diabetes in patients with pulmonary hypertension.

Abraham D Abernethy1, Kathryn Stackhouse2, Stephen Hart2, Ganesh Devendra2, Thomas M Bashore3, Raed Dweik4, Richard A Krasuski5.   

Abstract

Diabetes complicates management in a number of disease states and adversely impacts survival; how diabetes affects patients with pulmonary hypertension (PH) has not been well characterized. With insulin resistance having recently been demonstrated in PH, we sought to examine the impact of diabetes in these patients. Demographic characteristics, echo data, and invasive hemodynamic data were prospectively collected for 261 patients with PH referred for initial hemodynamic assessment. Diabetes was defined as documented insulin resistance or treatment with antidiabetic medications. Fifty-five patients (21%) had diabetes, and compared with nondiabetic patients, they were older (mean years ± SD, 61 ± 13 vs. 56 ± 16; [Formula: see text]), more likely to be black (29% vs. 14%; [Formula: see text]) and hypertensive (71% vs. 30%; [Formula: see text]), and had higher mean (±SD) serum creatinine levels (1.1 ± 0.5 vs. 1.0 ± 0.4; [Formula: see text]). Diabetic patients had similar World Health Organization functional class at presentation but were more likely to have pulmonary venous etiology of PH (24% vs. 10%; [Formula: see text]). Echo findings, including biventricular function, tricuspid regurgitation, and pressure estimates were similar. Invasive pulmonary pressures and cardiac output were similar, but right atrial pressure was appreciably higher (14 ± 8 mmHg vs. 10 ± 5 mmHg; [Formula: see text]). Despite similar management, survival was markedly worse and remained so after statistical adjustment. In summary, diabetic patients referred for assessment of PH were more likely to have pulmonary venous disease than nondiabetic patients with PH, with hemodynamics suggesting greater right-sided diastolic dysfunction. The markedly worse survival in these patients merits further study.

Entities:  

Keywords:  catheterization; diabetes; echo; pulmonary hypertension

Year:  2015        PMID: 25992276      PMCID: PMC4405710          DOI: 10.1086/679705

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  23 in total

1.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

3.  The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus.

Authors:  Mohammad-Reza Movahed; Mehrtash Hashemzadeh; M Mazen Jamal
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

4.  PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.

Authors:  Xianghuai Lu; Tamara C Murphy; Mark S Nanes; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-09       Impact factor: 5.464

5.  The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.

Authors:  Bum-Yong Kang; Jennifer M Kleinhenz; Tamara C Murphy; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-16       Impact factor: 5.464

6.  Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.

Authors:  Jinah Hwang; Dean J Kleinhenz; Bernard Lassègue; Kathy K Griendling; Sergey Dikalov; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2004-12-08       Impact factor: 4.249

7.  Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass.

Authors:  Lisa de las Fuentes; Angela L Brown; Santhosh J Mathews; Alan D Waggoner; Pablo F Soto; Robert J Gropler; Víctor G Dávila-Román
Journal:  Eur Heart J       Date:  2007-02-20       Impact factor: 29.983

8.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 9.  Heart disease in diabetic patients.

Authors:  Mihaela C Blendea; Samy I McFarlane; Esma R Isenovic; Gregory Gick; James R Sowers
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  18 in total

1.  Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan.

Authors:  Le-Yung Wang; Kuang-Tso Lee; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Tsu-Shiu Hsu; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 2.  Vascular Metabolic Mechanisms of Pulmonary Hypertension.

Authors:  Xiao-Fan Shi; Yun-Chao Su
Journal:  Curr Med Sci       Date:  2020-07-17

Review 3.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

4.  Insulin Resistance Is Associated with Right Ventricular Dysfunction.

Authors:  Jeff Min; Mary E Putt; Wei Yang; Nadine Al-Naamani; Alain G Bertoni; Joao A C Lima; R Graham Barr; Lauren Beussink-Nelson; Sanjiv J Shah; Steven M Kawut; Benjamin H Freed
Journal:  Ann Am Thorac Soc       Date:  2022-04

5.  The evolution of survival of pulmonary arterial hypertension over 15 years.

Authors:  Paul M Hendriks; Diederik P Staal; Liza D van de Groep; Leon M van den Toorn; Prewesh P Chandoesing; Robert M Kauling; Hans-Jurgen Mager; Annemien E van den Bosch; Marco C Post; Karin A Boomars
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

6.  Hypoxia-induced pulmonary hypertension in type 2 diabetic mice.

Authors:  Minglin Pan; Ying Han; Rui Si; Rui Guo; Ankit Desai; Ayako Makino
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

7.  Renin Angiotensin system-modifying therapies are associated with improved pulmonary health.

Authors:  Maira Soto; Soo I Bang; Jeff McCombs; Kathleen E Rodgers
Journal:  Clin Diabetes Endocrinol       Date:  2017-06-28

Review 8.  Diabetes and Lung Disease: A Neglected Relationship.

Authors:  Jasmin Khateeb; Eyal Fuchs; Mogher Khamaisi
Journal:  Rev Diabet Stud       Date:  2019-02-25

9.  The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Manuel Jonas Richter; Katrin Milger; Sarah Haase; Natascha Sommer; Khodr Tello; Werner Seeger; Eckhard Mayer; Christoph Benjamin Wiedenroth; Friedrich Grimminger; Wolfgang George; Hossein Ardeschir Ghofrani; Stefan Guth; Henning Gall
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

Review 10.  The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension.

Authors:  Daniel Grinnan; Grant Farr; Adam Fox; Lori Sweeney
Journal:  J Diabetes Res       Date:  2016-06-08       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.